Drug intelligence / Profile preview

LTI-004

Development stage: Preclinical
Lead developer: Leukogene Therapeutics
Modality: Recombinant Proteins and Enzymes

Overview

LTI-004 is a recombinant protein-based immunotherapy currently in preclinical development by Leukogene Therapeutics for the treatment of solid tumors. The drug is engineered using the company's proprietary M2T™ platform and acts as an MHC class II engager. While the specific molecular target beyond MHC class II remains undisclosed, the therapeutic approach aims to leverage MHC class II signaling to enhance anti-tumor immune responses.

Targets

HLA-DR (Human leukocyte antigen DR)

Beyond the preview

Go deeper on LTI-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LTI-004.

Explore the full profile